









市場
/
株式
/
nasdaq-abbv
/

AbbVie Inc

ABBV

223.430USD

+4.360+1.99%

終値 02/06, 16:00（ET）15分遅れの株価

394.88B時価総額

93.74直近12ヶ月PER



AbbVie Inc

223.430

+4.360+1.99%

概要金融分析企業名

概要

金融

分析

企業名

詳細情報 AbbVie Inc 企業名

AbbVie Inc. is a global, diversified research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).

AbbVie Incの企業情報



企業コードABBV

会社名AbbVie Inc

上場日Jan 02, 2013

最高経営責任者「CEO」Michael (Robert A)

従業員数55000

証券種類Ordinary Share

決算期末Jan 02

本社所在地1 N Waukegan Rd

都市NORTH CHICAGO

証券取引所NASDAQ OMX NASDAQ Basic NYSE

国United States of America

郵便番号60064

電話番号18479327900

ウェブサイトhttps://www.abbvie.com/

企業コードABBV

上場日Jan 02, 2013

最高経営責任者「CEO」Michael (Robert A)

AbbVie Incの経営陣



会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. Azita Saleki-Gerhardt, Ph.D.

Executive Vice President, Chief Operations Officer

183.77K

Mr. Thomas C. (Tom) Freyman, CPA

Independent Director

134.63K

+1203.00%

Mr. Edward J. (Ed) Rapp

Independent Director

42.95K

+1203.00%

Dr. Roopal Thakkar, M.D.

Executive Vice President - Research & Development, Chief Scientific Officer

42.28K

+5877.00%

Ms. Roxanne S. Austin, CPA

Lead Independent Director

38.46K

+1203.00%

Dr. Robert J. Alpern, M.D.

Independent Director

35.65K

+1203.00%

Mr. Frederick H. (Rick) Waddell

Independent Director

28.96K

+1203.00%

Ms. Melody B. Meyer

Independent Director

16.50K

+1203.00%

Mr. Timothy J. Richmond

Chief Human Resources Officer, Executive Vice President

6.13K

-21250.00%

Ms. Jennifer L. Davis

Independent Director

2.52K

+1203.00%

詳細を見る

会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. Azita Saleki-Gerhardt, Ph.D.

Executive Vice President, Chief Operations Officer

183.77K

Mr. Thomas C. (Tom) Freyman, CPA

Independent Director

134.63K

+1203.00%

Mr. Edward J. (Ed) Rapp

Independent Director

42.95K

+1203.00%

Dr. Roopal Thakkar, M.D.

Executive Vice President - Research & Development, Chief Scientific Officer

42.28K

+5877.00%

Ms. Roxanne S. Austin, CPA

Lead Independent Director

38.46K

+1203.00%

Dr. Robert J. Alpern, M.D.

Independent Director

35.65K

+1203.00%

収益内訳

通貨: USD更新時刻: Tue, Jan 6

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

事業別USD

会社名

収益

比率

Immunology-SKYRIZI

4.71B

29.84%

Immunology-RINVOQ

2.18B

13.84%

Immunology-HUMIRA

993.00M

6.29%

Neuroscience-Botox Therapeutic

985.00M

6.24%

Neuroscience-Vraylar

934.00M

5.92%

他の

5.97B

37.85%

地域別USD

会社名

収益

比率

United States

11.53B

73.07%

International

3.35B

21.21%

All other countries

660.00M

4.18%

Collaboration revenue

243.00M

1.54%

事業別

地域別

事業別USD

会社名

収益

比率

Immunology-SKYRIZI

4.71B

29.84%

Immunology-RINVOQ

2.18B

13.84%

Immunology-HUMIRA

993.00M

6.29%

Neuroscience-Botox Therapeutic

985.00M

6.24%

Neuroscience-Vraylar

934.00M

5.92%

他の

5.97B

37.85%

株主

更新時刻: Sun, Nov 16

株主統計

種類

株主統計

比率

The Vanguard Group, Inc.

10.18%

BlackRock Institutional Trust Company, N.A.

5.25%

State Street Investment Management (US)

4.52%

Geode Capital Management, L.L.C.

2.29%

JP Morgan Asset Management

2.06%

他の

75.70%

株主統計

比率

The Vanguard Group, Inc.

10.18%

BlackRock Institutional Trust Company, N.A.

5.25%

State Street Investment Management (US)

4.52%

Geode Capital Management, L.L.C.

2.29%

JP Morgan Asset Management

2.06%

他の

75.70%

種類

株主統計

比率

Investment Advisor

43.82%

Investment Advisor/Hedge Fund

20.45%

Research Firm

3.07%

Pension Fund

2.33%

Bank and Trust

2.31%

Sovereign Wealth Fund

1.41%

Hedge Fund

0.92%

Insurance Company

0.70%

Family Office

0.22%

他の

24.77%

機関投資家保有株



更新時刻: Mon, Dec 8

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q4

5311

1.33B

74.86%

+1.37M

2025Q3

5386

1.32B

74.95%

+8.86M

2025Q2

5326

1.32B

74.78%

+2.41M

2025Q1

5334

1.32B

74.15%

+3.84M

2024Q4

5267

1.31B

73.92%

+9.35M

2024Q3

4970

1.30B

74.13%

-1.24M

2024Q2

4907

1.30B

73.33%

+14.47M

2024Q1

4916

1.28B

72.48%

+1.37M

2023Q4

4861

1.27B

72.12%

+10.24M

2023Q3

4666

1.27B

72.28%

+8.75M

詳細を見る

株主動向



会社名

保有株式数

比率

変動額

変動率

日付

The Vanguard Group, Inc.

176.93M

10.01%

+427.57K

+0.24%

Sep 30, 2025

BlackRock Institutional Trust Company, N.A.

92.78M

5.25%

+679.67K

+0.74%

Sep 30, 2025

State Street Investment Management (US)

79.82M

4.52%

-202.47K

-0.25%

Sep 30, 2025

Geode Capital Management, L.L.C.

40.44M

2.29%

+1.26M

+3.22%

Sep 30, 2025

JP Morgan Asset Management

36.42M

2.06%

-1.05M

-2.81%

Sep 30, 2025

Charles Schwab Investment Management, Inc.

25.96M

1.47%

-825.22K

-3.08%

Sep 30, 2025

Capital Research Global Investors

25.23M

1.43%

-34.75K

-0.14%

Sep 30, 2025

Morgan Stanley Smith Barney LLC

23.97M

1.36%

+460.64K

+1.96%

Sep 30, 2025

Norges Bank Investment Management (NBIM)

23.10M

1.31%

-1.99M

-7.94%

Jun 30, 2025

Fidelity Management & Research Company LLC

19.95M

1.13%

+301.27K

+1.53%

Sep 30, 2025

詳細を見る

配当金



過去5年間の配当金総支払額は 40.87B 米ドルである。

日付

配当金

権利確定日

支払日

配当落ち日

Oct 31, 2025

ABBV.NB Interim Cash Dividend of gross USD 1.73 paid on Feb 17, 2026 going ex on Jan 16, 2026 with reinvestment option

Jan 16, 2026

Feb 17, 2026

Jan 16, 2026

Sep 05, 2025

ABBV.NB Final Cash Dividend of gross USD 1.64 paid on Nov 14, 2025 going ex on Oct 15, 2025 with reinvestment option

Oct 15, 2025

Nov 14, 2025

Oct 15, 2025

Jun 20, 2025

ABBV.NB Interim Cash Dividend of gross USD 1.64 paid on Aug 15, 2025 going ex on Jul 15, 2025 with reinvestment option

Jul 15, 2025

Aug 15, 2025

Jul 15, 2025

Feb 13, 2025

ABBV.NB Interim Cash Dividend of gross USD 1.64 paid on May 15, 2025 going ex on Apr 15, 2025 with reinvestment option

Apr 15, 2025

May 15, 2025

Apr 15, 2025

Oct 30, 2024

ABBV.NB Interim Cash Dividend of gross USD 1.64 paid on Feb 14, 2025 going ex on Jan 15, 2025 with reinvestment option

Jan 15, 2025

Feb 14, 2025

Jan 15, 2025

Oct 30, 2024

ABBV.NB Interim Cash Dividend of gross USD 1.64 paid on Feb 14, 2025 going ex on Jan 15, 2025

Jan 15, 2025

Feb 14, 2025

Jan 15, 2025

Sep 06, 2024

ABBV.NB Final Cash Dividend of gross USD 1.55 paid on Nov 15, 2024 going ex on Oct 15, 2024 with reinvestment option

Oct 15, 2024

Nov 15, 2024

Oct 15, 2024

Jun 21, 2024

ABBV.NB Interim Cash Dividend of gross USD 1.55 paid on Aug 15, 2024 going ex on Jul 15, 2024 with reinvestment option

Jul 15, 2024

Aug 15, 2024

Jul 15, 2024

Feb 15, 2024

ABBV.NB Interim Cash Dividend of gross USD 1.55 paid on May 15, 2024 going ex on Apr 12, 2024 with reinvestment option

Apr 15, 2024

May 15, 2024

Apr 12, 2024

Oct 27, 2023

ABBV.NB Interim Cash Dividend of gross USD 1.55 paid on Feb 15, 2024 going ex on Jan 12, 2024 with reinvestment option

Jan 16, 2024

Feb 15, 2024

Jan 12, 2024

詳細を見る

株式分割



日付

配当落ち日

種類

比率

データなし

日付

配当落ち日

種類

比率

データなし

KeyAI



AbbVie Inc

詳細情報 AbbVie Inc 企業名

AbbVie Incの企業情報

AbbVie Incの経営陣

収益内訳

株主

機関投資家保有株

株主動向

関連ETF

配当金

株式分割